ReviewRheumatology (Oxford, England)2021
A review and roadmap of the skin, lung and gut microbiota in systemic sclerosis.
Review in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- The Relationship Between Microbiota, Nutrition, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis: A Systematic Review of the Literature.International journal of molecular sciences · 2025Pooled it
- Axial Connectivity of the Lung Microbiome: A Review of Interorgan Crosstalk.Comprehensive physiology · 2026Review
- Gastrointestinal involvement in systemic sclerosis: A spotlight on small bowel involvement, complications and management.Best practice & research. Clinical rheumatology · 2026Review
- Exploring the anti-fibrotic effects of safflower in systemic sclerosis based on metabolomics and gut microbiota analyses.Frontiers in pharmacology · 2026Article
- Pathogenesis of systemic sclerosis: an integrative review of recent advances.Journal of rheumatic diseases · 2025Review
- An international perspective on the future of systemic sclerosis research.Nature reviews. Rheumatology · 2025Review
- Deficiency and altered phenotype of mucosal-associated invariant T cells in systemic sclerosis.Journal of scleroderma and related disorders · 2024Article
- Gut microbiome and metabolomics in systemic sclerosis: feature, link and mechanisms.Frontiers in immunology · 2024Review
- The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
As our understanding of the genetic underpinnings of SSc increases, questions regarding the environmental trigger(s) that induce and propagate SSc in the genetically predisposed individual emerge. The interplay between the environment, the immune system, and the microbial species that inhabit the patient's skin and gastrointestinal tract is a pathobiological frontier that is largely unexplored in SSc. The purpose of this review is to provide an overview of the methodologies, experimental study results and future roadmap for elucidating the relationship between the SSc host and his/her microbiome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.